Table 2.
Baseline characteristics of participants, by predicted 5-year risk of a major vascular event (MVE)
| Number of participants | Observed annual MVE rate in those allocated control or less statin | Observed annual MCE rate in those allocated control or less statin | Median follow-up in survivors (years)* | Women (%) | Mean age (SD; years) | Baseline LDL cholesterol (mmol/L)* | Diabetes (%) |
Baseline history of vascular disease (%) |
|||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Previous CHD | Other vascular† | None‡ | |||||||||
| Statin vs control | |||||||||||
| <5% | 24 790 | 0·6% | 0·2% | 4·0 | 54% | 59 (8) | 3·43 | 7% | 0% | 4% | 96% |
| ≥5% to <10% | 28 362 | 1·6% | 0·8% | 4·3 | 27% | 61 (9) | 3·68 | 18% | 2% | 11% | 87% |
| ≥10% to <20% | 38 504 | 3·4% | 1·5% | 4·7 | 29% | 64 (9) | 3·61 | 24% | 43% | 22% | 44% |
| ≥20% to <30% | 27 956 | 5·7% | 2·6% | 5·0 | 16% | 65 (9) | 3·72 | 19% | 80% | 28% | 13% |
| ≥30% | 14 925 | 9·5% | 5·1% | 4·9 | 14% | 66 (9) | 3·92 | 44% | 86% | 39% | 7% |
| Subtotal, 22 trials | 134 537 | 3·6% | 1·8% | 4·8 | 29% | 63 (9) | 3·70 | 21% | 39% | 20% | 52% |
| More vs less statin§ | |||||||||||
| ≥10% to <20%¶ | 18 050 | 3·7% | 1·6% | 5·9 | 22% | 60 (10) | 2·37 | 4% | 100% | 1% | 0% |
| ≥20% to <30% | 14 808 | 5·9% | 2·4% | 5·2 | 17% | 62 (9) | 2·59 | 17% | 100% | 12% | 0% |
| ≥30% | 6754 | 10·7% | 4·2% | 2·4 | 18% | 64 (10) | 2·81 | 35% | 100% | 35% | 0% |
| Subtotal, five trials | 39 612 | 5·3% | 2·2% | 5·1 | 19% | 62 (10) | 2·53 | 14% | 100% | 11% | 0% |
CHD=coronary heart disease. MCE=major coronary event.
Estimated using standard Kaplan-Meier methods with participants censored at their date of death; median follow-up and baseline LDL cholesterol for trial subgroups weighted by trial subgroup-specific variances of observed logrank (o–e) for major vascular events.
History of intracerebral bleed, transient ischaemic attack, ischaemic stroke, unknown stroke, peripheral artery disease or heart failure (if known).
No known history of CHD or other vascular disease.
The estimated 5-year major vascular event risk is with the less intensive statin regimen and observed MVE and MCE rates are for participants allocated the less intensive statin regimen; in three more versus less statin trials (A to Z, PROVE-IT, and IDEAL) there was no active run-in period before randomisation and so for the purpose of risk stratification and presentation of results the LDL cholesterol at baseline for the participants in these trials was adjusted for the observed LDL cholesterol reduction from baseline to year 1 in those allocated low intensity statin in the respective trial.
Includes 141 participants (48 [4 MVEs] from A to Z and 93 [11 MVEs] from SEARCH) with an estimated 5-year risk of MVE between 5% and 10%.